medigraphic.com
ISSN 0016-3813 (Impreso)

2002, Número S1

<< Anterior Siguiente >>

Gac Med Mex 2002; 138 (S1)


Retos y controversias en el paciente inmunocomprometido

I. Infección crónica activa por virus Epstein-Barr
II. Neutropenia febril. Manejo antimicrobiano según grupos de riesgo

Silva-López S, Paredes-Aguilera R, López-Hernández M

Idioma: Español
Referencias bibliográficas: 70
Paginas: 145-153
Archivo PDF: 69.40 Kb.


FRAGMENTO

Introducción

El riesgo de infección en un paciente con neutropenia y fiebre es inversamente proporcional al número absoluto o total de neutrófilos en sangre periférica, pacientes con neutropenia menor de 1000 cels/ml tienen 39%, de probabilidad de desarrollar una infección.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bodey. Quantitative relationship betwen circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966:64;328.

  2. Sickles. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715.

  3. Pizzo. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Eng J Med 1986;315:552.

  4. Reed. Characteristics of Gram-positive septicemia in patients with neutropenic fever. Proceedings of the Fifth International Symposium on Autologous Bone Marrow Transplation;1991. p. 267.

  5. Bodey. Fever and Infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978;41:1610.

  6. Burden. Viridans streptococcal bacteremia in patients with hematological and solid malignacy. Eur J Cancer 1991;27:409.

  7. Cohen. Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet 1983;2:1452.

  8. EORTC International Antimicrobial Therapy Project Group: three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14.

  9. Pizzo. Preventing infections in cancer patients. In: De Vita VT, editors. Cancer principles and practice of oncology, 3nd ed. Philadelphia, PA, USA: Lippincont, 1989. p. 2092.

  10. Goodman. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845.

  11. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients, J Infect Dis 1991;163:951.

  12. Karp. Empiric use of vancomycin during prolonged treatment-induced granulocy-topenia. Am J Med 1986;81:237.

  13. Rubin. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;103:30.

  14. Young. Antimicrobial prophylaxis in the neutropenic host: lessons of the past and perspective for the future. Eur J Clin Microbiol Infect Dis 1988;7:93.

  15. Henry. Symposium on infections complications of neoplastic disease. Part II. Chemoprophylaxis of bacterial infections in granulocytopenic patients. Am J Med 1984;76:645.

  16. Maher. Filgastrim in patients with chemoterapy-induced febrile neutropenia: a double-blind, placebo-controled trial. Ann Intern Med 1994;121:492.

  17. EORTC International Antimicrobial Therapy Cooperative Group. Empiric anti fungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668.

  18. Cassali. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia 1988;7:327.

  19. Hartlapp. Antimicrobial prophylaxis in inmunocompromised patients. Drugs 1987;34 (Suppl 1):131.

  20. Karp. Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987;106:1.

  21. Menichetti. Preventig fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913.

  22. Goodrich. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow-transplation. Ann Intern Med 1993;118:173.

  23. Schmidt. A randomized, controlled trial of prophylatic ganciclovir for cytomega lovirus-pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324:1005.

  24. Winston. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118:179.

  25. Winston. Ganciclovir prophylaxis in the neutropenic host: lessons of the past and perspective for the future. Eur J Clin Microbiol Infect Dis 1988. p. 7-93.

  26. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98:280-286.

  27. Okano M. Epstein-Barr virus infection and its role in the expanding spectrum of human diseases. Acta Pediatr 1998;87:11-18.

  28. Rickinson AB. Chronic, symptomatic Epstein-Barr virus infections. Immunol Today 1986;7:13-14.

  29. Ishihara S, Okada S, Wakiguchi T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Pediatr 1995;84:1271-1275.

  30. Sumazaki R, Kanegane H, Osaki M et al. SH2D1A mutations in Japanese males with severe Epstein/Barr virus-associated illnesses. Blood 2001;15:1268-1270.

  31. Sakai Y, Ohga S, Tonegawa Y et al. Interferon-a therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998;20:342-346.

  32. Gross TG. Treatment of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders. J Pediatr Hematol Oncol 2001;23:7-9.

  33. Hadad e, Paczensny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001;97:1590-1597.

  34. Bodey GP, Bolivar R, Fainstein V. Infectious complications in leukemic patients. Seminars in Hemat 1982; XIX (3):193-226.

  35. Bodey GP, Buckley M, Sathe YS. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-334.

  36. EORTC International Antimicrobial Therapy Project Group: three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137:14-32.

  37. Bodey GP, Middleman E, Umsawasdi T. Infections in cancer patients – results with gentamicin sulfate therapy. Cancer 1972; 29:1697-1701

  38. Freifeld AC, Walsh TJ, Pizzo PA. Clinical approaches to infections in the compromised host. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors Hematology, basic principles and practice 3nd ed. New York: 2000. p. 1443-1500.

  39. Lopez-Hernandez MA, Cuellar AI, De Diego FJ. Infección y neutropenia: pefloxacina versus amikacina-ceftazidima como terapia antimicrobiana empírica inicial. Med Inter Mex 1998;14: 208-212.

  40. Greene JN, Linch DC, Miller CB. Current treatments for infection in neutropenic patients with hematologic malignancy. Oncology (Huntingt) 2000 Aug;14(8 Suppl 6):31-34.

  41. Celebi H, Akan H, Akcaglayan E, Ustun C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant 2000 Jul;26(2):211-216.

  42. Klastersky J. Empirical treatment of sepsis in neutropenic patients. Int J Antimicrob Agents 2000 Oct;16(2):131-133.

  43. Schaumann R, Stein K, Eckhardt C, Ackermann G, Rodloff AC. Infections caused by Stenotrophomonas maltophilia a prospective study. Infection 2001 Aug;29(4):205-209.

  44. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001 May 15;32 (Suppl 2):S104-S110.

  45. Maschmeyer G. Use of the quinolones for the prophylaxis and therapy of infections in immuno-compromised hosts. Drugs 1993;4 (Suppl 3):73-80.

  46. Meisenberg B, Gollard R, Brehm T, McMillan R, Miller W. Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. Support Care Cancer 1996 Sep;4(5):364-369.

  47. Del Favero A, Menichetti F, Martino P, Mandelli F. Prevention of bacterial infection in neutropenic patients with hematological malignancies: a randomiced multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991;115:7-11.

  48. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethopim-sulfamethoxazole and colistin. Ann Intern Med 1987;106: 7-12.

  49. Trucksis M, Hopper DC, Wolfson JS. Emerging resistence to fluorquinolones in staphylococci: an alert. Ann Intern Med 1991;114:424-426.

  50. Gruson D, Hilbert G, Vargas F, Valentino R, Chene G, Boiron JM, Reiffers J, Gbikpi-Benissan G, Cardinaud JP. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med 2000 Sep;28(9):315.

  51. García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Tres A, Perez-Gracía JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001 Jan 3;93(1):31-35.

  52. López-Hernández MA, Jiménez-Alvarado R, Borbolla-Escoboza R, De Diego FJ, Alvarado-Ibarra M, González-Avante M, Trueba CE, Anaya CI. Factor estimulante de colonias de granulocitos en el tratamiento de la neutropenia febril. Gac Med Mex 2000;136 (2):99-105.

  53. De Pauw BE, Raemaekers JM, Schattenberg T, Donnelly JP. Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. J Intern Med Suppl 1997;740:69-74.

  54. Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R. Ambulatory treatment with ceftriaxone in febrile neutropenic children. J Med Sci 1994 Aug;30(8):649-654.

  55. Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia in patients at low risk. Infecti Dis Clini North Am 1996;10(2):224-229.

  56. Malik IA. Out-patient management of febrile neutropenia in indigent paediatric patients. Ann Acad Med Singapore 1997 Nov;26(6):742-749.

  57. Karthaus M, Meran JG, Geissler RG, Bohme A, Ganser A. Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia. Wien Med Wochenschr 1998;148(18):427-432.

  58. Karthaus M, Egerer G. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998 Jul;17(7):501-505.

  59. Papadimitris C, Dimopoulos MA, Kostis E, Papadimitriou C, Anagnostopoulos A, Alexopoulos G, Papamichael C, Gika D, Mitsibounas D, Stamatelopoulos S. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Oncology 1999;57(2):127-133.

  60. Sundararajan V, Rubenstein EB, Rolston KV, Elting LS. Controversies in new antibiotic therapy for ambulatory patients. Support Care Cancer 1997 Sep;5(5):358-364.

  61. Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, Gómez C, Ruiz A, García-Carbonero R, Cortes-Funes H. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999 Jan 1;85(1):213-219.

  62. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993 Jun 1;71(11): 3640-3646.

  63. Rapaport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, Iglesias L, Stein G, Charnas R, Heitlinger E, Handschin J. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard in-patient care. Chemotherapy 1999: Nov-Dec;45(6):466-476.

  64. Talcott JA, Whalen A, Clark J. Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.

  65. Castagnola E, Paola D, Giacchino R, Viscoli C. Clinical and laboratory features predicting a favorable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: a literature review. J Hematother Stem Cell Res 2000 Oct;9(5):645-649.

  66. Talcott JA. Out-patient management of febrile neutropenia. Int J Antimicrob Agents 2000;16(2):169-71.

  67. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999 Jul 1;86(1):126-34.

  68. Rolston KV. New trends in patients management: risk-based therapy for febrile patients with neutropenia. Clin Inf Dis 1999;29:515-521.

  69. Leese B. The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer 1993;29A Suppl 7:S15-8.

  70. Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect 2001; Feb;42(2):120-5.




2020     |     www.medigraphic.com